ÂÜÀòÂÒÂ×

Kenneth W Narducy, PhD, MBA, has spent more than 30 years in research and development at biomedical companies (including Abbott and Schering-Plough and the last 20 years with young biomedical companies). Three of the pharma companies in which he was a senior executive were acquired (Oculex by Allergan for $230 million, Centaur by Renovis [now Evotec] for $47 million, and St Charles Pharmaceuticals by Colby Pharmaceutical Company). Dr Narducy earned his PhD in Physical Organic Chemistry from Ohio State University and his MBA in Marketing and Finance from the University of Chicago.